Related references
Note: Only part of the references are listed.Disease activity and prognostic factors in juvenile dermatomyositis: a long-term follow-up study applying the Paediatric Rheumatology International Trials Organization criteria for inactive disease and the myositis disease activity assessment tool
Helga Sanner et al.
RHEUMATOLOGY (2014)
The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis
Dragana Lazarevic et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Serum concentration of interleukin 15, interleukin 2 receptor and TNF receptor in patients with polymyositis and dermatomyositis: correlation to disease activity
Pawel Mielnik et al.
RHEUMATOLOGY INTERNATIONAL (2012)
Pulmonary outcome in juvenile dermatomyositis: a case-control study
Helga Sanner et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Cardiac dysfunction in juvenile dermatomyositis: a case-control study
Thomas Schwartz et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Ablation of the Ccr2 Gene Exacerbates Polyarthritis in Interleukin-1 Receptor Antagonist-Deficient Mice
Hiroshi Fujii et al.
ARTHRITIS AND RHEUMATISM (2011)
Pathogenesis, classification and treatment of inflammatory myopathies
Mei Zong et al.
NATURE REVIEWS RHEUMATOLOGY (2011)
Type I interferon pathway in adult and juvenile dermatomyositis
Emily C. Baechler et al.
ARTHRITIS RESEARCH & THERAPY (2011)
MCP-1: Chemoattractant with a role beyond immunity: A review
Amita Yadav et al.
CLINICA CHIMICA ACTA (2010)
Circulating cytokine levels in mice with heart failure are etiology dependent
Maria Vistnes et al.
JOURNAL OF APPLIED PHYSIOLOGY (2010)
Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease
Takahisa Gono et al.
RHEUMATOLOGY (2010)
Idiopathic inflammatory myopathies, signified by distinctive peripheral cytokines, chemokines and the TNF family members B-cell activating factor and a proliferation inducing ligand
Peter Szodoray et al.
RHEUMATOLOGY (2010)
Eotaxin/CCL11 Levels Correlate With Myocardial Fibrosis and Mast Cell Density in Native and Transplanted Rat Hearts
M. Zweifel et al.
TRANSPLANTATION PROCEEDINGS (2010)
Long-Term Muscular Outcome and Predisposing and Prognostic Factors in Juvenile Dermatomyositis: A Case-Control Study
Helga Sanner et al.
ARTHRITIS CARE & RESEARCH (2010)
Long-Term Outcome and Prognostic Factors of Juvenile Dermatomyositis: A Multinational, Multicenter Study of 490 Patients
Angelo Ravelli et al.
ARTHRITIS CARE & RESEARCH (2010)
Interleukin-6 and Type I Interferon-Regulated Genes and Chemokines Mark Disease Activity in Dermatomyositis
Hatice Bilgic et al.
ARTHRITIS AND RHEUMATISM (2009)
Elevated Serum Interferon-α Activity in Juvenile Dermatomyositis Associations With Disease Activity at Diagnosis and After Thirty-Six Months of Therapy
Timothy B. Niewold et al.
ARTHRITIS AND RHEUMATISM (2009)
Role of cytokines and chemokines in idiopathic inflammatory myopathies
Boel De Paepe et al.
CURRENT OPINION IN RHEUMATOLOGY (2009)
Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset
Helga Sanner et al.
RHEUMATOLOGY (2009)
Modulation of CCR2 in rheumatoid arthritis - A double-blind, randomized, placebo-controlled clinical trial
Clarissa E. Vergunst et al.
ARTHRITIS AND RHEUMATISM (2008)
Up-regulated eotaxin plasma levels in chronic liver disease patients indicate hepatic inflammation, advanced fibrosis and adverse clinical course
Frank Tacke et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2007)
Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study
Wilco de Jager et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies
M. Tucci et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2006)
The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland) - clinical characteristics of children recruited within the first 5 yr
L. J. McCann et al.
RHEUMATOLOGY (2006)
A novel, selective, and orally available antagonist for CC chemokine receptor 3
T Morokata et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Duration of illness is an important variable for untreated children with juvenile dermatomyositis
LM Pachman et al.
JOURNAL OF PEDIATRICS (2006)
Role of eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis
F Huaux et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease
DA Isenberg et al.
RHEUMATOLOGY (2004)
Disease activity score for children with juvenile dermatomyositis: Reliability and validity evidence
RK Bode et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2003)
Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality
SM Sultan et al.
RHEUMATOLOGY (2002)
The CC chemokine eotaxin (CCL11) is a partial agonist of CC chemokine receptor 2b
R Martinelli et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Share Paper
